Unknown

Dataset Information

0

BA08: An open-label, single-arm, non-randomised, phase 2 trial of cisplatin, methotrexate and vinblastine (CMV) for pure squamous cell cancer of the urinary tract.


ABSTRACT:

Background

Pure squamous cell carcinoma (SCC) of the urinary tract is rare in the UK and has a poor prognosis compared with transitional cell carcinoma (TCC). Cisplatin based chemotherapy has been shown to be effective in TCC.

Methods

Patients with T3-T4, pelvic relapsed, nodal or metastatic SCC of the urinary tract were recruited into an open-label, single-arm, non-randomised, phase 2 trial evaluating the activity and safety of cisplatin, methotrexate and vinblastine (CMV) chemotherapy. CMV was given as three 21-day cycles of methotrexate 30mg/m2 (day 1 & 8), vinblastine 4mg/m2 (day 1 & 8) and cisplatin 100mg/m2 (day 2).

Results

38 patients were recruited. Overall response was 39% (95% CI 24%, 55%)-13% CR and 26% PR. Median OS was 7.8 months (95% CI 3.4, 12.6) with 39% 1-year survival. Toxicity was acceptable.

Conclusion

CMV is well tolerated and active in patients with pure SCC of the urinary tract.

SUBMITTER: Griffiths GO 

PROVIDER: S-EPMC6334943 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC10510135 | biostudies-literature
| S-EPMC7057274 | biostudies-literature
| S-EPMC8656312 | biostudies-literature
| S-EPMC6071437 | biostudies-literature
| PRJNA1173529 | ENA
| S-EPMC9558942 | biostudies-literature
| S-EPMC3255563 | biostudies-literature
| PRJNA717274 | ENA
| PRJNA912725 | ENA
| PRJDB14361 | ENA